These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15636683)

  • 21. New approaches in hormone refractory prostate cancer.
    Sonpavde G; Hutson TE
    Am J Clin Oncol; 2006 Apr; 29(2):196-201. PubMed ID: 16601442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiogenesis inhibitors in the treatment of prostate cancer.
    Kluetz PG; Figg WD; Dahut WL
    Expert Opin Pharmacother; 2010 Feb; 11(2):233-47. PubMed ID: 20088745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient.
    Gulley J; Dahut WL
    Urology; 2003 Dec; 62 Suppl 1():147-54. PubMed ID: 14747053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progress of molecular targeted therapies for prostate cancers.
    Fu W; Madan E; Yee M; Zhang H
    Biochim Biophys Acta; 2012 Apr; 1825(2):140-52. PubMed ID: 22146293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of prostate cancer. Part 3: metastatic disease.
    Shah J; Khaksar SJ; Sooriakumaran P
    Expert Rev Anticancer Ther; 2006 May; 6(5):813-21. PubMed ID: 16759171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches.
    van Moorselaar RJ; Voest EE
    Mol Cell Endocrinol; 2002 Nov; 197(1-2):239-50. PubMed ID: 12431818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug development in prostate cancer.
    Ripple GH; Wilding G
    Semin Oncol; 1999 Apr; 26(2):217-26. PubMed ID: 10597732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer.
    Collins R; Trowman R; Norman G; Light K; Birtle A; Fenwick E; Palmer S; Riemsma R
    Br J Cancer; 2006 Aug; 95(4):457-62. PubMed ID: 16880788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?
    Michels J; Montemurro T; Murray N; Kollmannsberger C; Nguyen Chi K
    Cancer; 2006 Mar; 106(5):1041-6. PubMed ID: 16456811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
    Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer.
    Koutsilieris M; Mitsiades C; Dimopoulos T; Vacalicos J; Lambou T; Tsintavis A; Milathianakis C; Bogdanos J; Karamanolakis D
    Expert Opin Investig Drugs; 2002 Feb; 11(2):283-93. PubMed ID: 11829717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment options in androgen-independent prostate cancer.
    Lara PN; Meyers FJ
    Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale.
    Ryan CJ; Lin AM; Small EJ
    Urol Oncol; 2006; 24(3):250-3. PubMed ID: 16678059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
    Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
    Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit study.
    Walczak JR; Carducci MA;
    Urology; 2003 Dec; 62 Suppl 1():141-6. PubMed ID: 14747052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment options for hormone-refractory prostate cancer].
    Heidenreich A; Ohlmann CH
    Urologe A; 2005 Nov; 44(11):1303-4, 1306-14. PubMed ID: 16237541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. P450-dependent enzymes as targets for prostate cancer therapy.
    De Coster R; Wouters W; Bruynseels J
    J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):133-43. PubMed ID: 8603034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of androgen receptor signaling in prostate cancer.
    Dehm SM; Tindall DJ
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):63-74. PubMed ID: 15757439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug design strategies for the treatment of prostate cancer.
    Lauer RC; Friend SC; Rietz C; Pasqualini R; Arap W
    Expert Opin Drug Discov; 2015 Jan; 10(1):81-90. PubMed ID: 25366417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversion of primary hyperfibrinogenolysis in patients with hormone-refractory prostate cancer using docetaxel.
    Sallah S; Gagnon GA
    Cancer Invest; 2000; 18(3):191-6. PubMed ID: 10754987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.